Market revenue in 2023 | USD 1,249.0 million |
Market revenue in 2030 | USD 2,054.4 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Synthetic |
Fastest growing segment | Biotech |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Synthetic, Biotech |
Key market players worldwide | Basf SE, CordenPharma, Bristol-Myers Squibb Co, Pfizer Inc, Boehringer Ingelheim Pharma, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Albany Molecular Research, Sanofi SA, Lonza Group Ltd, Cipla Ltd DR, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG ADR, Roche Holding AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to high potency active pharmaceutical ingredients market will help companies and investors design strategic landscapes.
Synthetic was the largest segment with a revenue share of 71.53% in 2023. Horizon Databook has segmented the China high potency active pharmaceutical ingredients market based on synthetic, biotech covering the revenue growth of each sub-segment from 2018 to 2030.
According to a study published by the UK NHS, healthcare expenditure in China is projected to reach USD 1 trillion, as the country has the largest population in the world. In addition, prevalence of chronic conditions such as cancer, cardiovascular diseases, diabetes, and obesity is increasing in China. These factors collectively create scope for HPAPI development.
In addition, cancer rates are high in China. For instance, in 2018, China reported 4.3 million new cancer cases. Government initiatives, such as NCD Prevention and Control Plan, is anticipated to improve access to oncology medications, which is expected to accelerate the growth of the market.
Moreover, biopharmaceutical sector is growing owing to high investments in R&D by the Chinese government. For instance, over USD 291 billion has been invested in biotechnology R&D by the Chinese government in the past few years. China is the largest producer of APIs and manufactures over 1,600 varieties of chemical APIs.
Horizon Databook provides a detailed overview of country-level data and insights on the China high potency active pharmaceutical ingredients market , including forecasts for subscribers. This country databook contains high-level insights into China high potency active pharmaceutical ingredients market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account